As Gamida Cell eyes its first cell therapy approval, Julian Adams is heading out
Julian Adams didn’t exactly finish what he set out to do at Gamida Cell, but it seems like he got close enough.
The seasoned biotech exec — who cemented his reputation at Millennium and then Infinity — is stepping down and passing the baton to Abigail Jenkins just after he steered the company toward its first BLA filing for a cell therapy. Gamida Cell is calling it a retirement, if that word still holds any weight in this industry.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.